The investigational compound bimagrumab developed by Novartis and Morphosys for patients suffering from sporadic inclusion body myositis has received breakthrough therapy designation from the FDA. The status was given to the drug because it shows substantial improvement in treating the condition over existing drugs. The drug shows promise in blocking inhibitory molecules and supporting muscle growth.

Full Story:

Related Summaries